Sanofi’s SNY stock has declined 10.2% in the past three months. However, a lot of this price decline was due to the downtrend ...

Alloy Therapeutics Inc. ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...

Sanofi SA (SNY) stock saw a modest uptick, ending the day at $49.19 which represents a slight increase of $1.04 or 2.16% from the prior close of $48.15. The stock opened at $48.57 and touched a low of ...

I-Mab has begun the new year with a pipeline pivot, pausing work on an asset that Sanofi bought into last year to focus on ...

Sanofi has enlisted drug discovery company Alloy Therapeutics to develop an antisense oligonucleotide drug for a single, undisclosed central nervous system target.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sanofi (SNYNF – Research Report) and Cencora ...

“Both companies are ‘houses of brands’, in other words a collection of well-diversified luxury businesses serving multiple ...

Berenberg Bank analyst Luisa Hector maintained a Buy rating on Sanofi (SNYNF – Research Report) today and set a price target of €115.00. The ...

Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level Mr. Shah Coherent Market Insights Pvt.

The increases are to list prices, which do not include rebates to pharmacy benefit managers and other discounts.

MRT-5410 is under clinical development by Sanofi and currently in Phase II for Unspecified Influenza Virus Infections.

SP-0230 is under clinical development by Sanofi and currently in Phase II for Neisseria meningitidis Infections.